

## عنوان مقاله:

Effect of Zinc Sulfate on Overall Survival and Progression-Free Survival in Patients with Glioblastoma Multiforme, a Phase II Study

## محل انتشار:

مجله سرطان خاورمیانه، دوره 14، شماره 1 (سال: 1402)

تعداد صفحات اصل مقاله: 6

## نویسندگان:

Niloofar Ahmadloo - *Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Parisa Kameli - *Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Mansour Ansari - *Breast Diseases Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Ahmad Mosalaei - *Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Shapour Omidvari - *Breast Diseases Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Hamid Nasrollahi - *Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Seyed Hassan Hamedei - *Radiation Oncology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

Mohammad Mohammadianpanah - *Colorectal Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran*

## خلاصه مقاله:

**Background:** Glioblastoma is the most prevalent and aggressive adult glial tumor. Patients who receive standard treatment have a mean survival of ۱۲-۱۴ months. Zinc is a micronutrient that has shown to have anticancerous effects. In the in vitro studies zinc had antineoplastic effects on glioblastoma cells. **Method:** This is a phase II randomized trial in which ۶۰ patients in two groups were evaluated. The zinc group (۲۹ patients) received zinc sulfate supplement ۵۰ mg orally twice a day and the control group (۳۱ patients) who were selected from historical case received no supplements. **Results:** Mean overall survival in the case and control groups were ۹.۹۳ ( $\pm ۳.۲۹$ ) and ۹.۰ ( $\pm ۳.۵۶$ ) months. In the case and control groups, the mean disease-free survival were ۹.۶۲ (SD  $\pm ۳.۳۷$ ) and ۸.۲۶ (SD  $\pm ۳.۴۷$ ) months. These differences were not statistically significant. Although overall survival and recurrence-free survival in patients in the case group was higher than the control group, there was no statistically significant difference ( $P =$

۰.۴۸۵). Conclusion: Zinc consumption was associated with better survival, but these differences were not statistically significant, necessitating further studies

## کلمات کلیدی:

Glioblastoma multiforme, Chemotherapy, Radiotherapy, Zinc sulfate

## لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/1819084>

